Our recent BHS guidelines for the management of small lymphocytic lymphoma (SLL) and chronic lymphocytic leukaemia (CLL) made by the BHS lymphoproliferative disease committee are not challenged after ASH 2020. One educational session discussed “chemotherapy-free frontline therapy for CLL” and “standard approaches for the relapsed/refractory (R/R) CLL after chemoimmunotherapy (CIT) or novel agents”. Managing toxicities of targeted therapies (BTKi, Pi3Ki, and venetoclax) was the topic of another educational session. Andrew Roberts highlighted the importance of bcl-2 inhibition in CLL and other hematological malignancies in the Ham-Wasserman session.
(BELG J HEMATOL 2021;12(1):25-8)